Site and Mechanism(s) of Expiratory Airflow Limitation in COPD, Emphysema and Asthma-COPD Overlap

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age30+
SponsorGelb, Arthur F., M.D.

About this trial

The purpose of this cross-sectional, observational study is to evaluate the site and mechanism(s) for expiratory airflow limitation in chronic, treated, current or former smokers (\>15 pack years) with COPD, Emphysema, and Asthma-COPD Overlap with mild to severe expiratory airflow limitation. Treatment may include short and long acting inhaled beta2agonists, short and long acting inhaled muscarinic receptor antagonists, inhaled and or oral corticosteroid, oral antibiotic, supplemental oxygen, and PDE type 4 inhibitor. In some cases, the patient may have had a history of asthma preceding the development of COPD (Asthma COPD Overlap).

Eligibility criteria

Qualifiers

asthma- copd overlap

emphysema in smokers with smoking history > 15 pack years

COPD/ bronchitis and bronchiectasis in smokers with smoking history

>15 pack years

Disqualifiers

non smokers

any other pulmonary diagnosis

pulmonary fibrosis

Trial design

Treatments tested in this trial

  • As above: diagnosis: COPD, Emphysema, Asthma-COPD Overlap

Treatment groups

60 Participants
are divided into 1 treatment group

Sponsors and collaborators